论文部分内容阅读
目的：考察１３１Ｉ－ＨＡｂ１８在正常人体内的生物学分布和器官辐射吸收剂量，为临床应用提供必需的依据。方法：一健康志愿者静脉给药后不同时间用Ｙ相机行全身及局部显像，并采取血样本及留全尿，按医学内照射剂量（ＭＩＲＤ）纲要计算器吸收剂量。结果：给药后１，４，２４，４８，７２，９６及１２０ｈ显像示血池，肝脏内放射性呈持续高水平，外生殖器及甲状腺亦显影。血中放射性持续清除，主要经肾由尿中排泄，给药后２４ｈ及４８ｈ分别排除给药量的２８．２％及６４．８％。器官吸收剂量（ｍＧＹ／ＭＢｑ）分别为：全身０．１８４，肝０．３６，甲状腺３．５７，睾丸１．８１。有效剂量当量（ＥＤＥ）为０．９５８ｍＳｖ／ＭＢｑ，受试者生命征无改变。结论：１３１Ｉ－ＨＡｂ１８用于人体是安全的，但应注意封闭甲状腺。
Objective: To investigate the biodistribution of 131I-HAb18 in normal human body and the dose of radiation absorbed by organs, so as to provide necessary basis for clinical application. METHODS: Whole body and local imaging were performed with a Y camera at different times after intravenous administration to a healthy volunteer, and blood samples and full urine were taken. The dose was absorbed by the MIRD outline calculator. RESULTS: At 1, 4, 24, 48, 72, 96, and 120 h after administration, the blood pool was visualized. The radioactivity in the liver was continuously high, and the external genitalia and thyroid gland were also visualized. Radioactivity in the blood continued to be cleared, mainly excreted by the kidneys from the urine, and 28.2% and 64.8% of the dose were excluded 24h and 48h after administration, respectively. The organs absorbed dose (mGY/MBq) were: whole body 0.184, liver 0.36, thyroid 3.57, testis 1.81. The effective dose equivalent (EDE) was 0.958 mSv/MBq, and there was no change in the subject’s vital signs. Conclusion: 131I-HAb18 is safe for use in humans, but it should be noted that the thyroid gland is closed.